Review anchor
Maltase-glucoamylase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Maltase-glucoamylase
CHEMBL2074
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Maltase-glucoamylase as ChEMBL target CHEMBL2074, mapped to UniProt O43451. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2074
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O43451
Maltase-glucoamylase
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Maltase-glucoamylase matters
Maltase-glucoamylase is reviewed as Maltase-glucoamylase (UniProt O43451); Maltase-glucoamylase shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 576 compounds, and 117 assays, with lead potency reaching pChEMBL 8.6.
Protein context
Maltase-glucoamylase
Maltase-glucoamylase Sequence length is 2753 aa.
Review this target as Maltase-glucoamylase, mapped to UniProt O43451. Sequence length is 2753 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O43451
Protein
Disease context
diabetes mellitus
Maltase-glucoamylase shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACARBOSE, MIGLITOL.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include ACARBOSE, MIGLITOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 6 approved drugs, 576 compounds, and 117 assays for this target. The dominant activity type is IC50. CHEMBL432221 is the current potency anchor at pChEMBL 8.6.
Use CHEMBL432221 as the tractability anchor when discussing potency (pChEMBL 8.6).
Activity source · ChEMBL 36 via Core Engine
6 approved
pChEMBL 8.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Maltase-glucoamylase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O43451, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why diabetes mellitus is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
576
Total Compounds
117
Total Assays
6
Approved Drugs
IC50: 429.0, KI: 53.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL432221
|
8.6 | Ki | — |
|
|
No preferred name
CHEMBL120226
|
8.4 | Ki | — |
|
|
No preferred name
CHEMBL2051983
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL2374254
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL3349432
|
8.2 | IC50 | — |
Approved Drugs
Source Header